Literature DB >> 20594595

Toll-like receptors: expression and involvement in multiple myeloma.

David Chiron1, Gaetan Jego, Catherine Pellat-Deuceunynck.   

Abstract

Multiple Myeloma (MM) cells express and respond to a broad range of TLRs. Accumulating evidences suggest that TLRs act as double-edged sword in MM biology. Indeed, TLR9 or TLR3 ligands could enhance immunity against MM cells or directly induce cell apoptosis, whereas various TLR agonists could induce MM survival, proliferation, and immune escape. This review is focused on the heterogeneous expression and function of TLRs in MM and on the potential implication of TLR ligands of infectious or endogenous origin in MM emergence, resistance, or progression.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594595     DOI: 10.1016/j.leukres.2010.06.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

2.  The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms.

Authors:  Woodrow J Coker; Ashley Jeter; Henning Schade; Yubin Kang
Journal:  Biomark Res       Date:  2013-02-04

4.  Construction of a Prognosis Model of the Pyroptosis-Related Gene in Multiple Myeloma and Screening of Core Genes.

Authors:  Can Li; Hongzheng Liang; Sicheng Bian; Xiaoxu Hou; Yanping Ma
Journal:  ACS Omega       Date:  2022-09-15

5.  Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells.

Authors:  J Abdi; T Mutis; J Garssen; F Redegeld
Journal:  Blood Cancer J       Date:  2013-05-31       Impact factor: 11.037

6.  TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling.

Authors:  Ying Chen; Jing Zhao; Dengzhe Li; Jinxia Hao; Pengcheng He; Huaiyu Wang; Mei Zhang
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.